Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed NSCLC with activated PI3K pathway * Progressive disease after prior systemic antineoplastic treatment(s) for advanced NSCLC * Archival or fresh tumor biopsy must be available for profiling * Measurable and/or non-measurable disease as per RECIST 1.1 criteria * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Adequate organ function as assessed by laboratory tests Exclusion Criteria: * Patient has received previous treatment with PI3K inhibitors * Patient with squamous NSCLC has received more than one line of chemotherapy treatment for metastatic disease; patient with non-squamous NSCLC has received more than two lines of systemic antineoplastic treatment for metastatic disease * Uncontrolled or symptomatic CNS metastases * Concurrent use of any other approved or investigational antineoplastic agent * Radiotherapy ≤ 28 days prior to starting study drug * Major surgery within 28 days prior to starting study drug * History of clinically significant cardiac dysfunction, mood disorders, or poorly controlled diabetes mellitus * Current treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes * Impairment of gastrointestinal (GI) function * Chronic treatment with steroids or another immunosuppressive agent. * Concurrent severe and/or uncontrolled medical condition * Currently receiving Warfarin or another coumarin derivative * Known history of HIV infection * Sensory neuropathy with functional impairment (CTC grade 2 neuropathy, regardless of causality) * Pregnancy, lactation, or breastfeeding * Woman of child-bearing potential Other protocol-defined inclusion/exclusion criteria may apply